Saelens, Xavier

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Wang, N., Van Breedam, W., Roose, K., van Schie, L., Hoffmann, M., Pöhlmann, S., et al. (2020) · Cell

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 610

Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses

De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S., et al. (2016) · Molecular Therapy

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 122

The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration

Van Hoecke, L., Roose, K., Ballegeer, M., Zhong, Z., Sanders, N. N., De Koker, S., Saelens, X., & Van Lint, S. (2020) · Molecular Therapy Nucleic Acids

Immunotherapy and Immune Responsesinterferon and immune responses

Cited by 55

Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice

Kakkola, L., Denisova, O. V., Tynell, J., Viiliäinen, J., Ysenbaert, T., Matos, R. C., Nagaraj, A., Öhman, T., Kuivanen, S., Paavilainen, H., et al. (2013) · Cell Death & Disease

Cell death mechanisms and regulationInfluenza Virus Research Studies

Cited by 54

Vaccines against human respiratory syncytial virus in clinical trials, where are we now?

Rossey, I., & Saelens, X. (2019) · Expert Review of Vaccines

Respiratory viral infections researchSARS-CoV-2 and COVID-19 Research

Cited by 32